Abstract
High-dose immunosuppressive therapy (HDIT) with autologous hematopoietic stem cell transplantation (AHSCT) is a promising approach to treatment of multiple sclerosis (MS) patients. In this paper, we present the long-term outcomes of a prospective single-center study with the analysis of the safety and efficacy of HDIT + AHSCT with reduced-intensity BEAM-like conditioning regimen in 99 MS patients: mean age—35 years old; male/female—39/60; median Expanded Disability Status Scale (EDSS) = 3.5; 43 relapsing/remitting MS, 56 progressive MS. No transplant-related deaths were observed. The mobilization and transplantation procedures were well tolerated. At 6 months post-transplant, neurological improvement or stabilization was observed in all the patients except one. Cumulative incidence of disease progression was 16.7 % at 8 years after HDIT + AHSCT. Estimated event-free survival at median follow-up of 48.9 months was 80 %: 83.3 % in relapsing/remitting MS vs 75.5 % in progressive MS. Sixty-four patients who did not progress during the first 3 years post-transplant and were monitored for more than 3 years were included in long-term outcome analysis. At the median long-term follow-up of 62 months, 47 % of patients improved by at least 0.5 points on the EDSS scale as compared to baseline and exhibited improvement during the entire period of follow-up; 45 % of patients were stable. No active, new, or enlarging lesions on magnetic resonance imaging were registered in patients without disease progression. AHSCT was accompanied by a significant improvement in patient’s quality of life. Due to the fact that patient selection was quite different to the other studies and that the information about disease activity prior in the disease course and its treatment was inhomogeneous, comparison with the results in the literature should be done with caution. Thus, the risk/benefit ratio of HDIT + AHSCT with reduced-intensity BEAM-like conditioning regimen in our population of MS patients is very favorable. The consistency of our long-term clinical and quality of life results, together with the persistence of improvement, is in favor of the efficacy and safety of this treatment approach in MS patients.
Similar content being viewed by others
References
Weinshenker BG (1995) The natural history of multiple sclerosis. Neurol Clin 3:119–146
Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, BaskervilleJ EGC (1989) The natural history of multiple sclerosis: a geographically based study. I Clinical course and disability. Brain 112:133–146
Compston A, Ebers G, Lassmann H, McDonald I, Matthews B, Wekerle H (1998) McAlpine’s multiple sclerosis, 3rd edn. Churchill Livingstone, Edinburgh
Fischer JM, Bramow S, Dal Biaco A et al (2009) The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 132:1175–1189
Burt RK, Cohen B, Rose J et al (2005) Hematopoietic stem cell transplantation for multiple sclerosis. Arch Neurol 62:860–864
Fassas A, Anagnostopoulos A, Kazis A et al (2000) Autologous stem cell transplantation in progressive multiple sclerosis—an interim analysis of efficacy. J Clin Immunol 20(1):24–30
Brenner MK (2004) Haematopoietic stem cell transplantation for autoimmune disease: limits and future potential. Best Pract Res Clin Haematol 17:359–374
Fassas A, Passweg JR, Anagnostopoulos A et al (2002) Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J Neurol 249:1088–1097
Kozak T, Havrdova E, Pit’ha J et al (2000) High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis. Bone Marrow Transplant 25:525–531
Saccardi R, Mancardi GL, Solari A et al (2005) Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood 105:2601–2607
Shevchenko Y, Novik A, Ionova T et al (2004) Clinical and quality of life outcomes in patients with multiple sclerosis after high-dose chemotherapy + autologous stem cell transplantation [abstract no. 1875]. Blood 104:519a
Shevchenko Y, Novik A, Kuznetsov A et al (2008) High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis. Exp Hematol 36(8):922–929
Ni XS, Ouyang J, Zhu WH, Wang C, Chen B (2006) Autologous hematopoietic stem cell transplantation for progressive multiple sclerosis: report of efficacy and safety at three yr of follow up in 21 patients. Clin Transplant 20:485–489
Saccardi R, Kozak T, Bocelli-Tyndall C et al (2006) Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult Scler 12:814–823
Hamerschlak N, Rodrigues M, Moraes DA et al (2010) Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM/horse ATG and CY/rabbit ATG. Bone Marrow Transplant 45(2):239–248
Rogojan C, Frederiksen JL (2009) Hematopoietic stem cell transplantation in multiple sclerosis. Acta Neurol Scand 120(6):371–382
Shevchenko J, Kuznetsov A, Ionova T et al (2012) Autologous hematopoietic stem cell transplantation with reduced intensity conditioning in multiple sclerosis. Exp Hem 40(11):892–898
Poser CM, Paty DW, Scheinberg L et al (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13(3):227–231
Hays RD, Sherbourne CD, Mazel RM. User’s manual for Medical Outcomes Study (MOS) core measures of health-related quality of life. RAND Corporation, MR-162-RC. http://www.rand.org
Snowden JA, Saccardi R, Allez M, Paediatric Diseases Working Party (PDWP) et al (2011) Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 47(6):770–790. doi:10.1038/bmt.2011.185
Kimiskidis VK, Fassas A (2013) Stem cell-based therapies in multiple sclerosis. J Genet Syndr Gene Ther S3. doi:10.4172/2157-7412.S3-006
Saccardi R, Freedman MS, Sormani MP et al (2012) A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper. Mult Scler 18(6):825–834
Reston JT, Uhl S, Treadwell JR, Nash RA, Schoelles K (2011) Autologous hematopoietic cell transplantation for multiple sclerosis: a systematic review. Mult Scler 17(2):204–213
Atkins HL, Freedman MS (2013) Hematopoietic stem cell therapy for multiple sclerosis: top 10 lessons learned. Neurotherapeutics 10:68–76
Burt RK, Cohen BA, Russell E et al (2003) Hematopoietic stem cell transplantation for progressive multiple sclerosis; failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood 102:2373–2378
Burman J, Iacobaeus E, Svenningsson A et al (2014) Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. J Neurol Neurosurg Psychiatry 19. doi:10.1136/jnnp-2013-307207
Bowen JD, Kraft GH, Wundes A et al (2012) Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results. Bone Marrow Transplant 47(7):946–951
Chen B, Zhou M, Ouyang J et al (2012) Long-term efficacy of autologous haematopoietic stem cell transplantation in multiple sclerosis at a single institution in China. Neurol Sci 33(4):881–886. doi:10.1007/s10072-011-0859-y
Fassas A, Kimiskidis VK, Sakellari I et al (2011) Long-term results of stem cell transplantation for MS: a single-center experience. Neurology 76(12):1066–1070
Burt RK, Marmont A, Oyama Y et al (2006) Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative transplant regimens. Arthritis Rheum 54:3750–3760
Mancardi G, Saccardi R (2008) Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol 7:626–636
Mancardi GL (2007) Present status of HSCT in MS. Mult Scler 13(2):22
Saiz A, Blanco Y, Carreras E et al (2004) Clinical and MRI outcome after autologous hematopoietic stem cell transplantation in MS. Neurology 62:282–284
Acknowledgments
We would like to acknowledge Andrei V. Kartashov (Moscow) and Ruslana V. Kruglina (Moscow) for their contribution to the study.
Conflict of interest
No financial interest/relationships with financial interest relating to the topic of this article have been declared.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shevchenko, J.L., Kuznetsov, A.N., Ionova, T.I. et al. Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician’s and patient’s perspectives. Ann Hematol 94, 1149–1157 (2015). https://doi.org/10.1007/s00277-015-2337-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-015-2337-8